The Bracken Group Blog — The Bracken Group | Colin G. Miller

Colin G. Miller

Ph.D, FIPEM, CSci, has been a leader in the development of medical imaging in clinical trials. He has more than 30 years in medical and scientific consulting. He also provides strategic development for the regulatory pathway and FDA interaction with respect to new diagnostics and end points in therapeutic clinical development. He has over 70 peer reviewed publications, 3 patents and published three books including “Medical Imaging in Clinical Trials” by Springer.

Recent Posts

25 February 2021

Time to Rethink RECIST 1.1?

Colin G. Miller

5 February 2021

Radiopharmaceuticals Hotter Than Ever - Infographic

Colin G. Miller

17 February 2020

Are Readers and Radiologist Calibration Meetings Important or Unnecessary?

Colin G. Miller

22 January 2020

[Infographic] Are Radiopharmaceuticals the New Hot Area in Biopharmaceuticals?

Colin G. Miller

24 September 2019

When is a Trial Registered in Clinicaltrials.gov?

Colin G. Miller

16 September 2019

Infographic- Ensure You're at the Top of Your Game with TBG's Help

Colin G. Miller

1 June 2019

The Role of Imaging Endpoints in Biosimilar Comparability

Colin G. Miller

1 June 2019

DCE-MRI Biomakers Technology and Development

Colin G. Miller

1 June 2019

Are Placebo-Controlled Trials in Osteoporosis Ethical?

Colin G. Miller

1 June 2019

The Use of Biomakers and PET in Early Alzheimer's Disease Diagnosis

Colin G. Miller